The United Arab Emirates continues to strengthen its position as a global leader in healthcare innovation through the approval of several advanced treatments in 2026.
The Emirates Drug Establishment approved “Baxfendy” by AstraZeneca for hypertension treatment, making the UAE the first country globally to authorise the medication.
The authority also approved “EURneffy,” the first needle-free epinephrine nasal spray for severe allergic reactions, becoming the first country in the region to approve the treatment.
Also read: RACGP Urges Immediate Release of cohealth Review and Long-Term Community Care Funding
Meanwhile, the Department of Health – Abu Dhabi introduced “Foundayo,” a daily oral obesity treatment integrated into its personalised weight management programme. The UAE became the second country globally, after the United States, to approve the therapy.
“These approvals reflect the UAE’s commitment to accelerating access to innovative therapies and strengthening its position as a leading destination for advanced healthcare solutions,” officials stated.
The approvals build on the UAE’s growing record in advanced healthcare, including pioneering treatments for multiple sclerosis, sickle cell disease, spinal muscular atrophy, Alzheimer’s disease, diabetes, and cancer immunotherapy.
